Please read and agree to the terms and conditions of this site.
@xconomy.com 5 years ago
Rani’s “Robotic Pill” for Biologics Clears First Hurdle in Humans
@xconomy.com 5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com 5 years ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More
@xconomy.com 5 years ago
Johnson & Johnson to Buy Robotics Startup Auris Health for $3.4B
@xconomy.com 5 years ago
Losing “Scalps”? Despite Pharma Fear, A Split on Trump Rx-Price Plans
@xconomy.com 5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com 5 years ago
Magnolia Medical Captures $20M to Reduce Blood Culture Contamination
@xconomy.com 5 years ago
With $100M MeiraGTx Deal, J&J Signals Bigger Move Into Gene Therapy
@xconomy.com 5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com 5 years ago
After 33 Exits in 5 Years, WI Seeks “More and Bigger” Startup Deals
@xconomy.com 5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com 5 years ago
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
@xconomy.com 5 years ago
Beta Bionics Secures $63M as AI-Driven “Pancreas” Heads to Key Tests
@xconomy.com 5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com 5 years ago
San Antonio Seeks to Be Known as Silicon Valley of Military Medicine
@xconomy.com 5 years ago
ASH 2018: Three Up, Two Down As The Big Blood Disease Meeting Rolls On
@xconomy.com 5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com 5 years ago
After Deal Stalled, Shine Medical Eyeing Up to $160M from Deerfield
@xconomy.com 5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com 5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel
@xconomy.com 5 years ago
MR3 Health Takes Aim at Foot Ulcers as San Antonio Tackles Diabetes
@xconomy.com 5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com 5 years ago
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections
@xconomy.com 5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com 5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com 5 years ago
InCube, VelocityTX Join Work to Develop Pediatric Medical Devices
@xconomy.com 5 years ago
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines
@xconomy.com 5 years ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way
@xconomy.com 5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com 5 years ago
San Antonio’s Spinal Stabilization Technologies Snags $11M Funding
@xconomy.com 5 years ago
Renovia Raises $42M to Back Digital Treatment for Incontinence
@xconomy.com 5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com 5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com 5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com 5 years ago
Sanofi Backs Click Therapeutics as Digital Medicines Gain Momentum
@xconomy.com 5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug
@xconomy.com 5 years ago
Boston Scientific Continues M&A Streak with $202M Deal for Cryterion
@xconomy.com 5 years ago
Virtual Physical Therapy Firms Reflexion and MindMaze Probe Markets
@xconomy.com 5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M
@xconomy.com 6 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine
@xconomy.com 6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More
@xconomy.com 6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines
@xconomy.com 6 years ago
Trump Pledges Lower Drug Prices, But Blueprint Is Short on Details
@xconomy.com 6 years ago
Histogen Treatment for Female Hair Loss Cleared for Clinical Testing
@xconomy.com 6 years ago
San Antonio Startup Adds Funding to Treat PTSD with Magnetic Field
@xconomy.com 6 years ago
United Therapeutics Reaches $141M Deal for PAH Drug Firm SteadyMed
@xconomy.com 6 years ago
Exact Sciences Beats Quarterly Forecasts, Sending Its Stock Price Up